Trastuzumab duocarmazine by Byondis for Gastric Cancer: Likelihood of Approval

Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Gastric Cancer.

Integrated care may not be the silver bullet for mental health treatment, study finds

Health care systems in the United States have gradually embraced the concept that mental health should be treated on par with physical health, especially in

December 29, 2023

The Double-Edged Sword of GenAI in the Life Sciences Sector

Rob Juncker, CTO of Code42 (now part of Mimecast) It’s said that data is the lifeblood of the modern enterprise. While that’s certainly true, it’s

October 28, 2024

Roundup: Medtech M&A slump continues but analysts predict uptick in 2024

Medtech M&A was down for the second straight year after an explosion of deal-making in 2021, with deal volumes down compared to prior years and

December 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.